Background: All-trans retinoid acid (ATRA) has been proven to skew Regulatory T cell-T helper 17 cell (Treg-Th17) balance toward Treg in vitro, favoring graft acceptance. However, its in vivo effect after solid organ transplantation is under investigation. Results: BALB/c mice were given orthotopic corneal grafts from C57BL/6 donors, and recipient mice were administered with ATRA, TGF-beta, and the combination of both agents for 8 weeks after surgery. We found that a mixed treatment of ATRA and TGF-beta significantly promoted graft survival. Moreover, with the presence of TGF-beta, ATRA upregulated CD4 (+)CD25(+) Foxp3(+) Treg cells and suppressed Th17 cells in the blood, spleen and draining lymph nodes of recipient mice, as well as enhanced the Foxp3 expression and inhibited the RORyt expression in grafts and peripheral blood mononuclear cells (PBMCs). Simultaneously, increased number of Foxp3+ cells and decreased number of IL-17+ cells in conjunctiva were found in recipients with mixed treatment, along with reduced IL-17 level in serum and aqueous humor and increased IL-10 level in aqueous humor. Tregs isolated from recipient mice treated with ATRA + TGF-beta presented the strongest suppressive activity in vitro. Conclusions: Combined application of ATRA and TGF-beta may shift the Th17-Treg balance toward Tregs, hence facilitating the induction of immunological tolerance after allogenic corneal transplantation and representing a potential therapeutic approach in the treatment of posttransplant rejection.
[1]Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
[2]Fudan Univ, Eye & ENT Hosp, Res Ctr, Shanghai 200031, Peoples R China.
(8.0+极速模式)